Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (191-200 of 252) with videos related to

Pageof 26
Sort By:
Hemasphere|June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upDennis A Eichenauer, Marc André, Peter Borchmann, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Frontiers in Immunology|October 10, 2024
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanomaKrasimira Aleksandrova, Jana Leise, Christoph Priesner, et al.
Hemasphere|November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
Blood Advances|March 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysisJulia Driessen, Fer de Wit, Alex F Herrera, et al.
Hemasphere|January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell TherapyConrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
Leukemia & Lymphoma|April 29, 2026
Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphomaLoretta Jo Nastoupil, Alejandro Martín García-Sancho, Koji Izutsu, et al.
Pageof 26

Showing results (191-200 of 252) with videos related to

Sort By:
Pageof 26
Hemasphere|June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upDennis A Eichenauer, Marc André, Peter Borchmann, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Frontiers in Immunology|October 10, 2024
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanomaKrasimira Aleksandrova, Jana Leise, Christoph Priesner, et al.
Hemasphere|November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
Blood Advances|March 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysisJulia Driessen, Fer de Wit, Alex F Herrera, et al.
Hemasphere|January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell TherapyConrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
Leukemia & Lymphoma|April 29, 2026
Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphomaLoretta Jo Nastoupil, Alejandro Martín García-Sancho, Koji Izutsu, et al.
Pageof 26